In 18F-positron emission tomography/computed tomography-guided precision radiotherapy for centrally located non-small cell lung cancer, tumor related atelectasis is a prognostic factor of survival

Nan Wang1, Yun Qiao2†, Yingqiu Song1†, Zheng Wang3†, Xia Li1, Chengsen Liu1, Ye Wang1, Yu Wu1, Rong He3, Chenyu Wang4, Yangwu Ren5, Guang Li6 and Tianlu Wang1*

1Department of Radiotherapy, Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, Shenyang, China, 2Department of Surgery, Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, Shenyang, China, 3Department of Cerebral Surgery, Liaoning Cancer Hospital & Institute, Shenyang, China, 4Department of Information Management, Liaoning Cancer Hospital & Institute, Shenyang, China, 5Department of Epidemiology, School of Public Health, China Medical University, Shenyang, China, 6Department of Radiotherapy, The First Hospital of China Medical University, Shenyang, China

Purpose: Tumor related atelectasis (TRA) is an essential factor affecting survival that can cause chest pain, cough, hemoptysis, chest tightness, dyspnea, and even death. In the current study, we explored the possible impact of TRA on survival in cancer patients and the guiding significance of 18F-positron emission tomography/computed (PET/CT) in radiotherapy for patients with atelectasis tumors.

Methods: In this retrospective study, we analyzed the treatment model and survival of patients with centrally located non-small cell lung cancer (NSCLC) treated with radiotherapy at two medical centers between May 2005 and August 2019. We identified 152 eligible patients and used propensity score matching (1:1) to process the data to reduce confounding factors, data bias, and mal-distribution.

Results: We used propensity scores created well-matched groups of 57 patients overall with or without TRA. The one-year survival rate of all patients was 71.9%, and the two-year survival rate was 33.3%. Compared to the atelectasis group, the overall survival (OS) of patients in the non-atelectasis
group was significantly prolonged (25 months vs. 17 months, \( p = 0.004 \)), as well as in the atelectasis recovery group (28 months vs. 14 months, \( p = 0.008 \)). In multivariate analysis, non-atelectasis was closely correlated with favorable OS (HR, 1.804 (−2.840); 95% CI, 1.145−2.840; \( p = 0.011 \)).

**Conclusion:** PET/CT can accurately stage NSCLC and better guide the treatment of NSCLC complicated with atelectasis. Tumor-associated atelectasis in patients with centrally located NSCLC can lead to a poor prognostic marker.

**KEYWORDS**
Centrally located NSCLC, Tumor related atelectasis, Prognostic factors, PET/CT, PSM

**Introduction**

In cases where lung cancer is complicated with atelectasis, it is challenging to distinguish tumors from normal atelectatic lung tissue (NALT) by computed tomography (CT) images, mainly due to morphological changes in anatomy and tissue density. The atelectatic lung tissue has considerable overlap with the imaging of tumor tissue due to edema, consolidation, and inflammatory reactions. Furthermore, both NALT and tumors tissue show high-density shadows on CT, so they are indistinguishable. However, determining the area of NALT and distinguishing it from the tumor tissue is very important to accurately delineate the radiotherapy target area and the treatment plan formulation (1, 2). The principle of 18F-positron emission tomography (18F-FDG PET) functional imaging is that the glucose metabolism rate of malignant tumor cells is higher than that of normal tissue cells. A previous study showed that FDG uptake in the atelectasis area is generally higher than normal lung parenchyma and lower than that in tumor tissue; since their concentration is different, the tumor tissue can be differentiated from the surrounding lung tissue (3). We previously reported (4) that PET/CT screening for non-small cell lung cancer (NSCLC) with atelectasis has significant advantages over traditional CT screening in guiding clinical treatment. PET/CT can make the clinical staging of NSCLC more accurate to design an appropriate treatment regimen, and improve the accuracy of target area when accompanied by NALT. Compared to CT, PET/CT can detect regional metastases and metastatic lymph nodes more effectively, and distinguish tumors and NALT more accurately, which improves the accuracy of radiotherapy target area (5, 6). Furthermore, according to the PET/CT images, three-dimensional conformal radiotherapy (3D-CRT) target area can be planned for the treatment of NSCLC, and reduce the exposure dose of the esophagus and spinal cord, thus facilitating an increase in radiotherapy dose (7). PET/CT-guided treatment can prolong the overall survival of patients with NSCLC (8).

The current TNM staging system considers TRA an adverse prognostic factor (9, 10), although a previous study has shown that TRA may prolong survival (11). Chen et al. has reported tumor-associated atelectasis had no significant effect on the survival of patients with superficial bronchial lung cancer (12). Moreover, Ou et al. has said that in stage IB NSCLC, tumor size determines hilar atelectasis or obstructive pneumonitis (13). The study by Coen et al. showed that partial or complete TRA might not affect overall survival (14). So far, the effect of TRA on the overall survival rate of radical radiotherapy for NSCLC has not been fully clarified. Therefore, we retrospectively analyzed whether TRA was a predictor for OS after PET/CT-guided definitive radiotherapy. Furthermore, we summarized the published clinical data in this setting and discussed the perspectives of PET/CT in radiation therapy for patients with centrally located NSCLC.

**Methods**

**Study population and sources**

We retrospectively reviewed NSCLC patients who underwent PET/CT examination (4, 15) at the Cancer Hospital of China Medical University and the First Hospital of China Medical University from May 2005 to August 2019. We reviewed patients’ electronic medical records and collected information such as age, gender, histological subtype, smoking history, radiographic, treatment, TRA, survival, state these variables. The inclusion criteria were patients with centrally located NSCLC who underwent PET/CT and received definitive radiation therapy. The complete basic information included whether the patients had a history of TRA and a clear re-expansion of the lungs after treatment? Our study used the
eighth edition of the TNM staging standard endorsed by the International Association for the Study of Lung Cancer (IASLC) (16). The standard treatment for unresectable locally advanced NSCLC (stage IIB-IIIC) was concurrent radiotherapy and chemotherapy or sequential radiotherapy and chemotherapy. For selected patients with stage IV (oligometastatic: number of metastases ≤5), the standard treatment was systemic chemotherapy combined with local consolidation radiotherapy. We grouped patients according to the presence or absence of TRA. The evaluation of adverse reactions after radiotherapy and chemotherapy is based on the General Adverse Event Terminology Standard (version 4.0).

As this study was a retrospective study, the risk to the subjects was very small, and we obtained the exemption of informed consent.

Propensity score matching (1:1)(PSM)

In the observational study, there are many data deviations and confounding variables due to various reasons. The propensity score matching method can make a more reasonable comparison between the experimental and control groups. We used IBM SPSS 25.0 software is used for propensity score matching, and used 1:1 nearest neighbor matching with 0.02 caliper width. The Chi-square test was used to evaluate the covariate balance before and after PSM in patients with TRA.

Statistical methods

Baseline and clinicopathological characteristics were described in numbers (percentages) and compared by chi-square test and fisher’s exact test. Overall survival was calculated from the date of diagnosis to the date of death or the survivor’s last follow-up. The OS curves were generated by Kaplan-Meier method and comparison was done by log-rank test. We used Cox proportional hazard mode for Univariate and multivariate analysis, and we reported the results using hazard ratios (HRs) with 95% confidence intervals (CIs). All tests were two sided, and the results were considered significant at p values<0.05. Subgroup analyses according to the baseline characteristics were performed by drawing forest plots for overall survival using IBM SPSS (version 25.0; IBM Corporation, Armonk, NY) software and Stata MP 14 software (Stata Corp LLC, College Station, TX).

Results

Patients characteristics

Of the 366 patients identified, 214 were excluded due to peripheral location of lung cancer, local surgery, incomplete data, or targeted therapy/immunotherapy; thus, a total of 152 eligible patients were included. The median follow-up period was 17 months. Of all patients, 34 patients are alive (22.4%), and 118 patients are deceased (77.6%). The causes of death included tumor-related complications (113 cases) and non-tumor complications (cerebrovascular events in 3 cases and myocardial infarction in 2 points). We created balanced groups of 57 patients with or without TRA through 1:1 PSM (Figure 1).

Analysis of prognostic factors

Tables 2, 3 show the results of univariate analysis before and after PSM, including the patient’s T stage of disease, whether TRA was present, and whether the lungs were re-expanded (all p < 0.1). Figure 2 shows that in patients with centrally located NSCLC who did not undergo surgery and who underwent radical radiotherapy, patients with TRA had a poor prognostic marker. For patients with TRA, re-expansion of the lungs represents a better prognosis, while non-TRA was associated with an apparent increase in the median OS (25 months vs. 17 months, p = 0.004). The OS of patients complicated with TRA was significantly improved after pulmonary dilatation (28 months vs. 14 months, p = 0.008) (Figure 3). Multivariate analysis showed that TRA was an independent factor predicting worse OS in patients with centrally located NSCLC receiving radical radiotherapy (p = 0.003) (Tables 4, 5).

Discussion

As far as we know, this is the most extensive retrospective study to date, aiming to evaluate the predictive value of TRA in patients with centrally located NSCLC treated with radiotherapy.
guided by PET/CT. We determined that TRA had a significantly negative prognostic indicator of OS in centrally located NSCLC after PET/CT-guided definitive radiotherapy. Moreover, lung re-expansion was a favorable independent prognostic factor in the TRA subgroup. Nonetheless, we found interesting results. There was no statistical difference in overall survival between the lung re-expansion and the no TRA group. The study further proves that TRA is a significant prognostic factor in patients with centrally located NSCLC, and we infer that the disease symptoms are improved after lung re-expansion. TRA is an important factor affecting survival that can cause chest pain, cough, hemoptysis, chest tightness, dyspnea, and even death. In addition, lung re-expansion improves tumor hypoxia and is increases chemoradiotherapy sensitivity; as we know, tumor hypoxia is a significant cause of tumor radiation resistance (6). Another factor related to prolonging survival is the control of infection and the improved immunity in lung re-expansion (6). Our study suggests that patients with atelectasis can be considered for radical radiotherapy under FDG-PET/CT guidance. We assume that mid/post-treatment lung re-expansion analysis is worth exploratory and would require further confirmation in future studies. After multivariate analysis, both clinical stage and TRA were independent prognostic factors.

Two main questions arose from the studies reported: First, is the T-classification in TNM staging applicable to patients with TRA? Based on anatomical image CT, the treatment plan and target area delineation developed for atelectasis patients should be done with functional imaging PET methods that includes multiple confounders. For example, the determination of tumor boundaries, disseminated lesions in unambiguous lung tissue, mediastinal lymph node overlap with TRA, and distant occult metastases. TRA, the most frequent thoracic complication in central lung cancer, has a considerable impact on the quality of life, making lung cancer patients' treatment more difficult. 18F-FDG PET/CT has good sensitivity to detect metastasis in systemic soft tissue, viscera (lungs, liver, adrenal gland, etc.), distant lymph nodes, and bones, and Several meta-analyses emphasized its role in accurate staging [17, 18]. Furthermore, an accurate depiction of the target volumes can prevent the omission of the radiotherapy target area. The wrong delineation of the gross tumor volume (GTV) (detectable tumor) is a common mistake. The incorrect tracing of target areas will lead to insufficient radiotherapy dose and reduce local control rate. With the development of 3D radiotherapy technology, we can delineate accurate treatment plan based on three-dimensional reconstruction of CT images, evaluate the treatment volume, and overall scheme, further optimize the radiation dose in the tumor area, reach the radical cure standard, and reduce the radiation effect on normal tissues (19). Secondly, When lung cancer is complicated with TRA, it is difficult to determine the tumor area only by anatomical images such as CT, which will inevitably affect the treatment results. In contrast to previous studies (11–14), this study retrospective study included cases treated using functional imaging PET/CT guidance to develop treatment plan, outline target areas, and establish radiotherapy plans. Our previous study (8) showed that radiation treatment guided by PET-CT had a better outcome in the similar stage than radiation treatment without PET-CT guidance.

The standard treatment for unresectable locally advanced NSCLC (stage IIB-IIIC) in our study was concurrent radiotherapy and chemotherapy or sequential radiotherapy and chemotherapy.
In our study, the standard of care for most patients was concurrent radiotherapy and chemotherapy or sequential radiotherapy and chemotherapy. The definitive radiation treatment for unresectable locally advanced NSCLC (stage IIB-IIIC) is an equivalent dose of 60–66 Gy/30f(BED). For patients (in selected cases) with stage IV (oligometastatic), the standard treatment in our study was systematic chemotherapy combined with local consolidation radiotherapy (50-60 Gy). The purpose of consolidation radiation is to improve the control rate of the primary tumor area and prevent distant metastasis. In our previous study, local consolidation treatment for patients with stage IV oligometastatic NSCLC can improve patient outcomes to some extent (20). Local consolidation treatment may cause modest toxicity, but can improve overall survival. Using PET/CT pretreatment characterization of tumors using PET/CT may help patients find the most suitable treatment, accurately customize radiotherapy plans, and select chemotherapeutics. Incorrect GTV depiction may lead to insufficient dose to the tumor, leading to local control failure and/or increased toxicity due to radiation of normal tissue. However, it may be

| TABLE 1 Baseline characteristics of patients. | BEFORE PSM* |  | AFTER PSM* |
|---------------------------------------------|------------|---|------------|
| characteristics                           | No TRA (N=63)(%) | TRA (N=89)(%) | P | No TRA (N=57)(%) | TRA (N=57)(%) | P |
| Age (years)                                |            |               |   |            |               |   |
| <65                                        | 36 (57.1)  | 56 (62.9)     | 0.473 | 35 (61.4)  | 35 (61.4)     | 1 |
| ≥65                                        | 27 (42.9)  | 33 (37.1)     | 22 (38.6) | 22 (38.6)  |               |   |
| Gender                                     |            |               |   |            |               |   |
| Male                                       | 44 (69.8)  | 76 (85.4)     | 0.021 | 44 (77.1)  | 44 (77.1)     | 1 |
| Female                                     | 19 (30.2)  | 13 (14.7)     | 13 (22.9) | 13 (22.9)  |               |   |
| Smoking                                    |            |               |   |            |               |   |
| No                                         | 33 (52.4)  | 62 (69.7)     | 0.03 | 29 (50.9)  | 38 (66.7)     | 0.087 |
| Yes                                        | 30 (47.6)  | 27 (30.3)     | 28 (49.1) | 19 (33.3)  |               |   |
| Pathological pattern                       |            |               |   |            |               |   |
| Squamous carcinoma                         | 35 (55.6)  | 71 (79.8)     | 0.005 | 34 (59.6)  | 43 (75.4)     | 0.184 |
| Adenocarcinoma                             | 18 (28.6)  | 13 (14.7)     | 15 (26.3) | 10 (17.5)  |               |   |
| Other                                       | 10 (15.9)  | 5 (5.6)       | 8 (14.1)  | 4 (7.1)    |               |   |
| Weight loss                                |            |               |   |            |               |   |
| 5%                                         | 39 (61.9)  | 67 (75.3)     | 0.077 | 37 (64.9)  | 46 (80.7)     | 0.058 |
| ≥5%                                        | 24 (38.1)  | 22 (24.7)     | 20 (35.1) | 11 (19.3)  |               |   |
| KPS                                        |            |               |   |            |               |   |
| >80                                        | 58 (92.1)  | 84 (94.4)     | 0.57 | 53 (91)    | 53 (91)       | 1 |
| ≤80                                        | 5 (7.9)    | 5 (5.6)       | 4 (7)     | 4 (7)      |               |   |
| T classification                           |            |               |   |            |               |   |
| T1-2                                       | 19 (30.2)  | 18 (20.2)     | 0.16 | 17 (29.8)  | 14 (24.6)     | 0.528 |
| T3-4                                       | 44 (69.8)  | 71 (79.8)     | 40 (70.2) | 43 (75.4)  |               |   |
| N classification                           |            |               |   |            |               |   |
| N0-1                                       | 13 (20.6)  | 23 (25.8)     | 0.457 | 12 (21.1)  | 15 (26.3)     | 0.509 |
| N2-3                                       | 50 (79.4)  | 66 (74.2)     | 45 (78.9) | 42 (73.7)  |               |   |
| Stages                                     |            |               |   |            |               |   |
| Ib                                         | 6 (9.5)    | 9 (10.1)      | 0.159 | 5 (8.8)    | 6 (10.5)      | 0.233 |
| Ila                                        | 14 (22.2)  | 15 (23.8)     | 13 (22.8) | 10 (17.5)  |               |   |
| IIIb                                       | 23 (36.5)  | 35 (55.6)     | 21 (36.8) | 19 (33.3)  |               |   |
| IIIC                                       | 13 (20.6)  | 9 (14.3)      | 11 (19.3) | 6 (10.5)   |               |   |
| IV                                         | 7 (11.1)   | 21 (23.6)     | 7 (12.3)  | 16 (28.1)  |               |   |
| Chemotherapy                               |            |               |   |            |               |   |
| No                                         | 28 (44.4)  | 28 (31.5)     | 0.102 | 26 (45.6)  | 18 (31.6)     | 0.124 |
| Yes                                        | 35 (55.6)  | 61 (68.5)     | 31 (54.4) | 39 (38.4)  |               |   |

*a The PSM was performed using age, sex, which were subdivided according to the median values.

b Fourfold table: sample size ≥ 40, 1 ≤ least 2 theoretical frequencies < 5, using Fisher’s exact test

n, number of cases/controls; PSM, propensity score matching.
challenging to depict GTV entirely based on planned CT scans and is affected by differences within and between observers (4). When tumors and surrounding tissues with similar densities appear on CT images, their contrast is limited, making it more challenging to determine GTV. Especially in the presence of TRA (lung collapse or closure), mediastinal invasion, and GTV should include mediastinal lymph nodes. The inclusion of FDG-PET images in radiotherapy planning has been shown to reduce intra observer and inter-observer variability and improve the clarity of GTV (21). In addition, there is a good correlation between the tumor size determined by resected pathological specimens and the tumor size in preoperative PET/CT images (22). In the use of FDG-PET/CT images to guide radiation treatment planning, using the 3D-CRT/IMRT radiotherapy technique, we select some stage IV NSCLC high palliative chest consolidation measures. Dose escalation is carried out

| TABLE 2 Uniformity analyses of association between prognostic factors and overall survival (Before PSM). |
|---------------------------------------------------------------|
| characteristics       | n  | median survival time (months) | 1-year os (%) | 2-years os (%) | X²     | P    |
|------------------------|----|-------------------------------|---------------|---------------|--------|------|
| Age (years)            |    |                               |               |               |        |      |
| <65                    | 92 | 19                            | 69.6          | 26.1          | 2.55   | 0.576|
| ≥65                    | 60 | 22                            | 70.0          | 38.3          |        |      |
| Gender                 |    |                               |               |               |        |      |
| Male                   | 120| 20                            | 69.2          | 28.3          | 1.787  | 0.819|
| Female                 | 32 | 19                            | 71.9          | 40.6          |        |      |
| Smoking                |    |                               |               |               |        |      |
| No                     | 95 | 19                            | 64.2          | 28.4          | 0.741  | 0.363|
| Yes                    | 57 | 21                            | 78.9          | 35.1          |        |      |
| Pathological pattern   |    |                               |               |               |        |      |
| squamous carcinoma     | 106| 19                            | 67.9          | 28.3          | 1.262  | 0.159|
| adenocarcinoma         | 31 | 27                            | 71.0          | 38.7          |        |      |
| else                   | 15 | 22                            | 80.0          | 33.3          |        |      |
| Weight loss            |    |                               |               |               |        |      |
| <5%                    | 106| 22                            | 72.6          | 33.0          | 0.722  | 0.086|
| ≥5%                    | 46 | 14                            | 63.0          | 26.1          |        |      |
| KPS                    |    |                               |               |               |        |      |
| >80                    | 142| 20                            | 67.6          | 28.9          | 4.238  | 0.997|
| ≤60                    | 10 | 27                            | 100.0         | 60.0          |        |      |
| T classification       |    |                               |               |               |        |      |
| T1-2                   | 37 | 23                            | 81.1          | 35.1          | 0.407  | 0.21 |
| T3-4                   | 115| 19                            | 66.1          | 29.6          |        |      |
| N classification       |    |                               |               |               |        |      |
| N0-1                   | 36 | 24                            | 83.3          | 38.9          | 1.402  | 0.184|
| N2-3                   | 116| 17                            | 65.5          | 28.4          |        |      |
| Stages                 |    |                               |               |               |        |      |
| IBb                    | 15 | 24                            | 93.3          | 33.3          | 7.739  | 0.002|
| IIIa                   | 29 | 27                            | 82.8          | 44.8          |        |      |
| IIIb                   | 58 | 21                            | 69.0          | 32.8          |        |      |
| IIIc                   | 22 | 12                            | 54.5          | 9.1           |        |      |
| IV                     | 28 | 12                            | 57.1          | 28.6          |        |      |
| Chemotherapy           |    |                               |               |               |        |      |
| No                     | 56 | 15                            | 62.5          | 32.1          | 0.062  | 0.42 |
| Yes                    | 96 | 22                            | 74.0          | 30.2          |        |      |
| TRA                    |    |                               |               |               |        |      |
| No                     | 63 | 24                            | 76.2          | 38.1          | 2.593  | 0.003|
| Yes                    | 89 | 17                            | 65.2          | 25.8          |        |      |
| Lung re-expansion      |    |                               |               |               |        |      |
| No                     | 66 | 14                            | 63.6          | 22.7          | 3.753  | 0.006|
| Yes                    | 23 | 28                            | 69.6          | 34.8          |        |      |
through integrated enhancement technology and will not exceed the dose limit of normal organs and tissues. Similar strategies were used with both TRA and no TRA, whereby the prescribed dose was increased to residual tumor volumes. In contrast to previous studies, the same approach was used in our patients: Patients underwent FDG-PET/CT-guided 3D-CRT/IMRT radiotherapy, with dose escalation to residual tumor areas after 14–20 fractions of radiotherapy, combined with (concurrent or sequential) chemotherapy or solely radiotherapy. There was no significant difference between the TRA and no TRA groups in terms of toxic side effects after chemoradiotherapy, both of which were below grade 3. Furthermore, our previous results (5) showed that this PET CT guided treatment approach was superior to the outcomes of patients based on CT-guided

| characteristics     | n  | median survival time (months) | 1-year os (%) | 2-years os (%) | X²  | P   |
|---------------------|----|-------------------------------|---------------|---------------|-----|-----|
| Age (years)         |    |                               |               |               |     |     |
| <65                 | 70 | 20                            | 72.9          | 30.0          | 0.907 | 0.584 |
| ≥65                 | 44 | 22                            | 70.5          | 38.6          |     |     |
| Gender              |    |                               |               |               |     |     |
| Male                | 88 | 21                            | 72.7          | 30.7          | 1.221 | 0.912 |
| Female              | 26 | 19                            | 69.2          | 42.3          |     |     |
| Smoking             |    |                               |               |               |     |     |
| No                  | 67 | 19                            | 65.7          | 29.9          | 0.887 | 0.261 |
| Yes                 | 47 | 27                            | 80.9          | 38.3          |     |     |
| Pathological pattern|    |                               |               |               |     |     |
| squamous carcinoma  | 77 | 19                            | 70.1          | 29.9          | 1.696 | 0.098 |
| adenocarcinoma      | 25 | 31                            | 76.0          | 44.0          |     |     |
| else                | 12 | 22                            | 75.0          | 33.3          |     |     |
| Weight loss         |    |                               |               |               |     |     |
| <5%                 | 83 | 22                            | 75.9          | 34.9          | 0.354 | 0.375 |
| ≥5%                 | 31 | 16                            | 61.3          | 29.0          |     |     |
| KPS                 |    |                               |               |               |     |     |
| >80                 | 106| 20                            | 69.8          | 31.1          | 3.294 | 0.965 |
| ≤80                 | 8  | 27                            | 100.0         | 62.5          |     |     |
| T classification    |    |                               |               |               |     |     |
| T1-2                | 31 | 25                            | 83.9          | 35.5          | 0.089 | 0.009 |
| T3-4                | 83 | 19                            | 67.5          | 32.5          |     |     |
| N classification    |    |                               |               |               |     |     |
| N0-1                | 27 | 22                            | 85.2          | 37.0          | 0.218 | 0.363 |
| N2-3                | 87 | 19                            | 67.8          | 32.2          |     |     |
| Stages              |    |                               |               |               |     |     |
| IBb                 | 11 | 22                            | 90.9          | 27.3          | 5.986 | 0.015 |
| IIIa                | 23 | 27                            | 87.0          | 47.8          |     |     |
| IIIb                | 40 | 24                            | 70.0          | 35.0          |     |     |
| IIIc                | 17 | 13                            | 58.8          | 11.8          |     |     |
| IV                  | 23 | 14                            | 60.9          | 34.8          |     |     |
| Chemotherapy        |    |                               |               |               |     |     |
| No                  | 44 | 16                            | 61.4          | 31.8          | 0.074 | 0.202 |
| Yes                 | 70 | 24                            | 78.6          | 34.3          |     |     |
| Atelectasis         |    |                               |               |               |     |     |
| No                  | 57 | 25                            | 75.4          | 38.6          | 1.421 | 0.004 |
| Yes                 | 57 | 17                            | 68.4          | 28.1          |     |     |
| Lung re-expansion   |    |                               |               |               |     |     |
| No                  | 41 | 14                            | 65.9          | 22.0          | 3.882 | 0.008 |
| Yes                 | 16 | 28                            | 75            | 43.8          |     |     |
radiotherapy regimens during the same period at the same institution. This could be related to collapse and hypoxia of lung parenchyma. Atelectasis and obstructive pneumonia caused by bronchial compression or involvement are important causes of death in patients with lung cancer (6). Hypoxia induces increased cellular glucose uptake, and proximal tumors in the airway often lead to atelectasis and bronchial obstruction.

This study is a retrospective study. The sample size is relatively small and there is heterogeneity between cases, which is prone to selection bias and recall bias. In addition, due to the large time span, this study lacks corresponding clinical data on the impact of driver gene positive related targeted therapy and immunotherapy on the overall survival of oligometastatic NSCLC patients in recent years, and does not study the cause of death of patients.

Taken together, our results demonstrate that PET/CT guided radiation treatment plan has distinct advantages in guiding patients with atelectasis to 3D-CRT/IMRT radiotherapy. Moreover, it can accurately stage lung cancer, develop a standardized, accurate, and effective treatment plan based on precise staging, and better complete radiotherapy by mapping the target area. TRA and T stage are strongly correlated with unfavorable prognosis in patients with centrally located NSCLC definitive radiotherapy under the guidance of PET/CT. Active treatment of TRA can prolong the survival of patients, while lung re-expansion can improve the prognosis of atelectasis patients.

TABLE 4 Multivariate analysis between prognostic factors and overall survival (Before PSM).

| Factor          | B   | Sx | P    | HR (95%CI)         |
|-----------------|-----|----|------|-------------------|
| T1~2 vs. T3~4   | .200| .244| .412 | 1.221 (0.758-1.969) |
| No Atelectasis vs. Atelectasis | .580| .205| .005 | 1.786 (1.196-2.667) |

TABLE 5 Multivariate analysis between prognostic factors and overall survival (After PSM).

| Factor          | B   | Sx | P    | HR (95%CI)         |
|-----------------|-----|----|------|-------------------|
| T1~2 vs. T3~4   | .408| .282| .148 | 1.504 (0.865-2.614) |
| No Atelectasis vs. Atelectasis | .590| .232| .011 | 1.804 (1.145-2.840) |

Stages(IIb/IIIa/IIIb/IIIc/IV) | .240| .078| .025 | 1.272 (1.091-1.482) |
Since the small number of patients with lung re-expansion after chemoradiotherapy limits its applicability, we caution that post/mid-treatment lung re-expansion analysis should be considered exploratory until further validation in larger cohorts.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

The ethics committees approved the retrospective protocol of the current study of Cancer Hospital of Chinese Medical University and The First Hospital of China Medical University, which was conducted in accordance with the Declaration of Helsinki. Since all data are anonymous, the requirement of informed consent is exempted.

Author contributions

Conceptualization: TW and GL; data curation: NW, YS, and YQ; formal analysis: NW, YS, and ZW; statistical analysis: YS and ZW; validation: NW; visualization: YR and C-YW; writing the original draft: NW, YS, and YQ; draft review & editing: all authors.; modify and polish: all authors; funding acquisition: all authors.; 7. Song YQ, Wang TL, Dang J, Li YM, Li G, et al. Analysis of the therapeutic results and prognosis of atretic non-small cell lung cancer with PET/CT. Chin Oncol (2017) 26(01):68–72.

References

1. Ding XP, Li H, Wang Z, Huang W, Li B, Zang R, et al. Feasibility of shrinking field radiation therapy through 18F-FDG PET/CT after 40 Gy for stage III non-small cell lung cancers. Asian Pac J Cancer Prev (2012) 13:319–23. doi: 10.7314/APJCP.2012.13.3.319
2. Yun L-J, Yu X-B, Ren Y-G, Gu G-H, Ding T-G, Lu Z. Utilization of PET-CT in target volume delineation for three-dimensional conformal radiotherapy in patients with non-small cell lung cancer and atelectasis. Multidiscip Respir Med (2013) 8(1):21-27. doi: 10.1186/2049-6958-8-21
3. Gerbaudo VH, Julius B. Anatomo-metabolic characteristics of atelectasis in F-18 FDG-PET/CT imaging. Eur J Radiol (2007) 64:401–5. doi: 10.1016/j.ejrad.2007.08.013
4. Wang TL, Li G, Dang J, Chen YZ, Bai L. Effects on the PET-CT NSCLC clinical staging dimensional conformal radiotherapy target delineation. Chin J Radiat Oncol (2011) 20(2):99–100.
5. Wang TL, Sing YQ, Dang J, Cai F, Yao L, Li YM, et al. Impact of PET/CT on the target volume delineation and treatment management of non-small cell lung cancer complicated with atelectasis. Chin J Nucl Med Mol Imaging (2012) 32 (2):115–8.
6. Hasbek Z, Yuced B, Salk I, Turgut B, Erselcan T, Babacan NA, et al. Potential impact of atelectasis and primary tumor glycolysis on F-18 FDG PET/CT of survival in lung cancer patients. Asian Pac J Cancer Prev (2014) 15:4085–9. doi: 10.7314/APJCP.2014.15.9.4085
7. Song YQ, Wang TL, Dang J, Li YM, Li G, et al. Analysis of the therapeutic results and prognosis of atretic non-small cell lung cancer with PET/CT. Chin Oncol (2017) 26(01):68–72.
8. Song YQ, Wang TL, Dang J, et al. Prognostic factors of IV stage non-small cell lung cancer and the potential significance of thoracic radiotherapy. J Med Oncol (2018) 26(08):1207–11.
9. Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallières E, Groome P, et al. The IASLC lung cancer staging project: External validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer: J Thorac Oncol (2017) 12:1109–21. doi: 10.1016/j.jtho.2017.04.011
10. Groome Patti A, Bolejack V, Crowley Jj, Kennedy C, Krasnik M, Sobin LH, et al. The IASLC lung cancer staging project: Validation of the proposals for revision of the T, n, and m descriptors and consequent stage groupings in the forthcoming (Seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol (2007) 2(8):694–705.
11. Bulbul Y, Oztuna F, Topa M, Teflik O., et al. Survival analyses of patients with thoracic complications secondary to bronchial carcinoma at the time of diagnosis. Respiratio (2005) 72:388–94. doi: 10.1159/000086253
12. Chen C, Zheng H, Gao W, Zhou Y, Jiang S, Suen H, et al. Prognosis and staging of superficial endobronchial lung cancer: The impact of invasion depth, tumor diameter, and coexistent pneumonitis or atelectasis. Chin Med J (2010) 123 (12):1505–9.
13. Ou SH, Zell JA, Zogas A, Anton-Culver H. Prognostic significance of the non-Size-Based AJCC T2 descriptors: Visceral pleura invasion, hilar atelectasis, or obstructive pneumonitis in stage IB non-small cell lung cancer is dependent on tumor size. Chest (2008) 133:662–9. doi: 10.1378/chest.07-1506

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Funding

The Liaoning Province Natural Science Foundation [2020-ZLH-47][2020-MS-065], Medical Industry Cross Joint Fund of Liaoning Province (Dalian University of Technology)[2021-YGJC-02], Liaoning Province Key Area Joint Open Fund [2019-KF-01-01], Tumor Mass spectrometry Center project[2ZP20019] [ZP202008], Key Laboratory of Tumor Radiosensitization and Normal Tissue Radioprotection Project of Liaoning Province (2018225102), Shenyang Major Scientific Research Projects (19–112–4–090).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
14. Coen V, Van Lancker M, De Neve W, Storme G. Prognostic factors in locoregional non-small cell lung cancer treated with radiotherapy. *Am J Clin Oncol* (1995) 18:111–7. doi:10.1097/00000421-199504000-00004

15. Wang TL, Li G, Song YQ, Dang J, Chen YZ, Bai L, et al. Impact of PET/CT on dosimetric parameters of three-dimensional conformal radiotherapy planning in patients with non-small cell lung cancer. *Chin J Cancer Prev Treat* (2012) 19 (4):284–6.

16. Asamura H, Chansky K, Crowley J, Goldstraw P, Rusch VW, Vansteenkiste JF, et al. The international association for the study of lung cancer lung cancer staging project: Proposals for the revision of the n descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. *J Thorac Oncol* (2015) 10:1675–84. doi:10.1097/JTO.0000000000000678

17. Li J, Xu W, Kong F, Sun X, Zuo X. Meta-analysis: Accuracy of 18FDG PET-CT for distant metastasis staging in lung cancer patients. *Surg Oncol* (2013) 22:151–5. doi: 10.1016/j.suronc.2013.04.001

18. Qu X, Huang X, Yan W, Wu L, Dai K, et al. A meta-analysis of 18FDG-PET–CT, 18fdg-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. *Eur J Radiol* (2012) 81(5):0-1015. doi: 10.1016/j.ejrad.2011.01.126

19. Lee Karla A, Rangaswamy G, Lavan NA, Dunne M, Collins CD, Small C, et al. ICORG 06-35: A prospective evaluation of PET-CT scan in patients with non-operable or non-resectable non-small cell lung cancer treated by radical 3-dimensional conformal radiation therapy: A phase II Study.[J]. *Jr J Med Sci* (2019) 188:1155–61. doi: 10.1007/s11843-019-02019-2

20. Song YQ, Wang N, Qiao Y, He L, Li X, Zhang XF, et al. Treatment patterns and survival after 18F-fluorodeoxyglucose positron emission Tomography/Computed tomography-guided local consolidation therapy for oligometastatic non-small cell lung cancer: A two-center propensity score-matched analysis. *J Cancer Res Clin Oncol* (2020) 146:1021–31. doi: 10.1007/s00432-020-03334-9

21. Xiao L, Liu N, Zhang G, Zhang H, Gao S, Fu Z, et al. Late-course adaptive adjustment based on metabolic tumor volume changes during radiotherapy may reduce radiation toxicity in patients with non-small cell lung cancer. *PLoS One* (2017) 12:e0170901. doi: 10.1371/journal.pone.0170901

22. Brunese I, Greco B, Setola FR, Lassandro F, Guarracino MR, et al. Non-small cell lung cancer evaluated with quantitative contrast-enhanced CT and PET-CT: net enhancement and standardized uptake values are related to tumour size and histology. *Med Sci Monit* (2013) 19:95–101. doi: 10.12659/MSM.883759